Oleg Gluz
University of Cologne(DE)Bethesda Hospital(IN)Deutsches Archäologisches Institut, Zentrale(DE)Hochschule Niederrhein(DE)Breast Center(CH)Klinik Niederrhein(DE)Evangelisches Krankenhaus Bethesda Mönchengladbach(DE)Women‘s Healthcare Group(DE)University Hospital Cologne(DE)
Publications by Year
Research Areas
Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies, Cancer Treatment and Pharmacology, Cancer Genomics and Diagnostics
Most-Cited Works
- → Triple-negative breast cancer—current status and future directions(2009)684 cited
- → West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment(2016)361 cited
- → Trastuzumab emtansine (T-DM1) renders HER2 + breast cancer highly susceptible to CTLA-4/PD-1 blockade(2015)329 cited
- → The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice(2020)219 cited
- → Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial(2017)187 cited
- → De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel